Home Tags Enfortumab vedotin

Tag: enfortumab vedotin

Updated Results from Trial Shows Enfortumab Vedotin + Pembrolizumab to Shrink...

Updated findings from EV-103, a phase Ib/II clinical trials of enfortumab vedotin* (Padcev™; Astellas Pharma/Seattle Genetics) in combination with pembrolizumab (Keytruda®; Merck Sharp &...

Novel Treatments are a Positive Development for Patients with Metastatic Urothelial...

This week has brought welcome news to bladder cancer patients and their loved ones. Two drugs with great potential for combatting different types of...

Enfortumab Vedotin + Pembrolizumab to be Evaluated in Phase III...

Enfortumab vedotin (also known as AGS-22ME; Seattle Genetics/Astellas), an antibody-drug conjugate (ADC), will be evaluated in a phase III clinical trial in combination with...
General images of ESMO 2019 Congress being held in Barcelona, Spain, September 27 - October 1, 2019. Courtesy European Society for Medical Oncology (ESMO). Used with Permission.

ESMO 2019: Combination of Enfortumab Vedotin + Pembrolizumab Shows High ORR...

Initial results from EV-103, a phase I clinical trial (NCT03288545) of the investigational antibody-drug conjugate enfortumab vedotin (also known as AGS-22ME; Seattle Genetics/Astellas) in...
Featured Image: Annual Congress of ESMO 2018. Courtesy: © 2018 European Society for Medical Oncology. Used with permission.

ESMO 2019: Seattle Genetics to Present Initial Data from a Phase...

Less than a week before the start of the annual meeting of the European Society for Medical Oncology (ESMO), to be held September 27...
Astellas Pharma, Exhibition booth during ASCO 2019, held May 31 – June 4, 2019 in Chicago, Ill.| Courtsey: Emila Duaerte / Sunvalley Communication

U.S. FDA Grants Priority Review for Enfortumab Vedotin Biologics License Application...

The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for the investigational agent enfortumab vedotin, also known as ASG-22CE,...
Astellas Pharma. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Astellas and Seattle Genetics file BLA for Enfortumab Vedotin

Japanese drugmaker Astellas Pharma and Seattle Genetics confirmed the submission of a Biologics License Application (BLA) for accelerated approval to the U.S. Food and...
Astellas Pharma, Exhibition booth during ASCO 2019, held May 31 – June 4, 2019 in Chicago, Ill.| Courtsey: Emila Duaerte / Sunvalley Communication

Enfortumab Vedotin Produces High Tumor Response in Metastatic Urothelial Cancer

Enfortumab vedotin (also known as ASG-22CE), an investigational antibody-drug conjugates being developed by Seattle Genetics in collaboration with Astellas Pharma, showed a positive, high...

Pivotal Trial of Enfortumab Vedotin Shows Positive Topline Results in Locally...

The first cohort of patients in a pivotal phase II single-arm clinical trial, known as EV-201, shows positive topline results. EV-201 is an ongoing...

Breakthrough Therapy Designation Granted for Enfortumab Vedotin in Locally Advanced or...

This week the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate or ADC, for patients with...